Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions : meta-analysis of individual patient data. / Zimmermann, Frederik M; Omerovic, Elmir; Fournier, Stephane; Kelbæk, Henning; Johnson, Nils P; Rothenbühler, Martina; Xaplanteris, Panagiotis; Abdel-Wahab, Mohamed; Barbato, Emanuele; Høfsten, Dan Eik; Tonino, Pim A L; Boxma-de Klerk, Bianca M; Fearon, William F; Køber, Lars; Smits, Pieter C; De Bruyne, Bernard; Pijls, Nico H J; Jüni, Peter; Engstrøm, Thomas.

I: European Heart Journal, Bind 40, Nr. 2, 07.01.2019, s. 180-186.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Zimmermann, FM, Omerovic, E, Fournier, S, Kelbæk, H, Johnson, NP, Rothenbühler, M, Xaplanteris, P, Abdel-Wahab, M, Barbato, E, Høfsten, DE, Tonino, PAL, Boxma-de Klerk, BM, Fearon, WF, Køber, L, Smits, PC, De Bruyne, B, Pijls, NHJ, Jüni, P & Engstrøm, T 2019, 'Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data', European Heart Journal, bind 40, nr. 2, s. 180-186. https://doi.org/10.1093/eurheartj/ehy812

APA

Zimmermann, F. M., Omerovic, E., Fournier, S., Kelbæk, H., Johnson, N. P., Rothenbühler, M., Xaplanteris, P., Abdel-Wahab, M., Barbato, E., Høfsten, D. E., Tonino, P. A. L., Boxma-de Klerk, B. M., Fearon, W. F., Køber, L., Smits, P. C., De Bruyne, B., Pijls, N. H. J., Jüni, P., & Engstrøm, T. (2019). Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. European Heart Journal, 40(2), 180-186. https://doi.org/10.1093/eurheartj/ehy812

Vancouver

Zimmermann FM, Omerovic E, Fournier S, Kelbæk H, Johnson NP, Rothenbühler M o.a. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. European Heart Journal. 2019 jan. 7;40(2):180-186. https://doi.org/10.1093/eurheartj/ehy812

Author

Zimmermann, Frederik M ; Omerovic, Elmir ; Fournier, Stephane ; Kelbæk, Henning ; Johnson, Nils P ; Rothenbühler, Martina ; Xaplanteris, Panagiotis ; Abdel-Wahab, Mohamed ; Barbato, Emanuele ; Høfsten, Dan Eik ; Tonino, Pim A L ; Boxma-de Klerk, Bianca M ; Fearon, William F ; Køber, Lars ; Smits, Pieter C ; De Bruyne, Bernard ; Pijls, Nico H J ; Jüni, Peter ; Engstrøm, Thomas. / Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions : meta-analysis of individual patient data. I: European Heart Journal. 2019 ; Bind 40, Nr. 2. s. 180-186.

Bibtex

@article{6b43daf14ff6436ab31858d9ee5e0e4d,
title = "Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data",
abstract = "Aims: To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with contemporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy in patients with stable coronary lesions.Methods and results: We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 randomly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12-60 months), a reduction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy (hazard ratio 0.72, 95% confidence interval 0.54-0.96; P = 0.02). The difference between groups was driven by MI.Conclusion: In this IPD meta-analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a decreased risk of MI.",
author = "Zimmermann, {Frederik M} and Elmir Omerovic and Stephane Fournier and Henning Kelb{\ae}k and Johnson, {Nils P} and Martina Rothenb{\"u}hler and Panagiotis Xaplanteris and Mohamed Abdel-Wahab and Emanuele Barbato and H{\o}fsten, {Dan Eik} and Tonino, {Pim A L} and {Boxma-de Klerk}, {Bianca M} and Fearon, {William F} and Lars K{\o}ber and Smits, {Pieter C} and {De Bruyne}, Bernard and Pijls, {Nico H J} and Peter J{\"u}ni and Thomas Engstr{\o}m",
year = "2019",
month = jan,
day = "7",
doi = "10.1093/eurheartj/ehy812",
language = "English",
volume = "40",
pages = "180--186",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions

T2 - meta-analysis of individual patient data

AU - Zimmermann, Frederik M

AU - Omerovic, Elmir

AU - Fournier, Stephane

AU - Kelbæk, Henning

AU - Johnson, Nils P

AU - Rothenbühler, Martina

AU - Xaplanteris, Panagiotis

AU - Abdel-Wahab, Mohamed

AU - Barbato, Emanuele

AU - Høfsten, Dan Eik

AU - Tonino, Pim A L

AU - Boxma-de Klerk, Bianca M

AU - Fearon, William F

AU - Køber, Lars

AU - Smits, Pieter C

AU - De Bruyne, Bernard

AU - Pijls, Nico H J

AU - Jüni, Peter

AU - Engstrøm, Thomas

PY - 2019/1/7

Y1 - 2019/1/7

N2 - Aims: To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with contemporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy in patients with stable coronary lesions.Methods and results: We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 randomly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12-60 months), a reduction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy (hazard ratio 0.72, 95% confidence interval 0.54-0.96; P = 0.02). The difference between groups was driven by MI.Conclusion: In this IPD meta-analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a decreased risk of MI.

AB - Aims: To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with contemporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy in patients with stable coronary lesions.Methods and results: We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 randomly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12-60 months), a reduction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy (hazard ratio 0.72, 95% confidence interval 0.54-0.96; P = 0.02). The difference between groups was driven by MI.Conclusion: In this IPD meta-analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a decreased risk of MI.

U2 - 10.1093/eurheartj/ehy812

DO - 10.1093/eurheartj/ehy812

M3 - Journal article

C2 - 30596995

VL - 40

SP - 180

EP - 186

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 2

ER -

ID: 234021778